{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:32:27Z","timestamp":1778571147058,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2014,12]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>This clinical review aims to assess the efficacy of human papillomavirus 16\/18 (HPV<\/jats:styled-content>16\/18) vaccination on the cell\u2010mediated immune response in women with existing cervical intraepithelial neoplasia or cervical cancer induced by HPV<\/jats:styled-content>16 or HPV<\/jats:styled-content>18.<\/jats:p><\/jats:sec>Data sources and study selection<\/jats:title>A focused and thorough literature search conducted in five different databases found 996 publications. Six relevant articles were chosen for further review. In total, 154 patients (>18\u00a0years of age) were enrolled in prospective study trials with 3\u201315\u00a0months of follow up. The vaccine applications were administered two to four times. The vaccines contained different combinations of HPV<\/jats:styled-content>16 and HPV<\/jats:styled-content>18 and early proteins, E6 and E7. The primary outcome was the cell\u2010mediated immune response. Correlation to clinical outcome (histopathology) and human leukocyte antigen genes were secondary endpoints.<\/jats:p><\/jats:sec>Results<\/jats:title>All vaccines triggered a detectable cell\u2010mediated immune response, some of which were statistically significant. Correlations between immunological response and clinical outcome (histopathology) were not significant, so neoplasms may not be susceptible to vaccine\u2010generated cytotoxic T cells (CD<\/jats:styled-content>8+<\/jats:sup>).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Prophylactic HPV<\/jats:styled-content> vaccines have been introduced to reduce the incidence of cervical cancer in young women. Women already infected with HPV<\/jats:styled-content> could benefit from a therapeutic HPV<\/jats:styled-content> vaccination. Hence, it is important to continue the development of therapeutic HPV<\/jats:styled-content> vaccines to lower the rate of HPV<\/jats:styled-content>\u2010associated malignancies and crucial to evaluate vaccine efficacy clinically. This clinical review represents an attempt to elucidate the theories supporting the development of an HPV<\/jats:styled-content> vaccine with a therapeutic effect on human papillomavirus\u2010induced malignancies of the cervix.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.12480","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T15:43:40Z","timestamp":1408635820000},"page":"1209-1218","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cell\u2010mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination"],"prefix":"10.1111","volume":"93","author":[{"given":"Sonja Izquierdo","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Aarhus University Hospital, Skejby Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine","family":"Fuglsang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Aarhus University Hospital, Skejby Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Blaakaer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Aarhus University Hospital, Skejby Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.05.036"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-235"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57149"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1999.0141"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_2_8_7_1","first-page":"3676","article-title":"Safety and immunogenicity of TA\u2010HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)\u201016 and HPV\u201018 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann AM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_8_1","volume-title":"HPV and the Vaccines: Myths and Misconceptions. Immunological Answers to Key Questions","author":"Singer A","year":"2009"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.10.1473"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.51240"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/157339410791202583"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.04.007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000067923"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007323"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2011.01277.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1725"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23022"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0501-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101308"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.12480","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.12480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:35:52Z","timestamp":1695573352000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.12480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/aogs.12480"],"URL":"https:\/\/doi.org\/10.1111\/aogs.12480","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]},"assertion":[{"value":"2013-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}